Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses.

"Declarations Ethical approval and consent to participateThis study was approved by the Mass General Brigham Institutional Review Board (#2021P003536) and a waiver was granted for the need for consent of participants. All research activities were conducted in accordance with the Declaration of Helsinki. Competing interestsThe authors have no competing interests relevant to this article to disclose. Dr. Weiss receives royalties from UpToDate and is on the board of Histolix. Competing interests The authors have no competing interests relevant to this article to disclose. Dr. Weiss receives royalties from UpToDate and is on the board of Histolix."

"Funding Dr. Akenroye is supported by the Harvard Diversity Inclusion and Community Partnership (DICP) Fellowship Award and by the Brigham and Women’s Hospital Minority Faculty Career Development Award. Dr. Moll is supported by K08HL159318 from NHLBI. Dr. Weiss is supported in part by R01HL161362 from NHLBI."